Piroxicam

Research use only, not for human use.

Piroxicam is a non-selective COX inhibitor.

Piroxicam is a non-selective COX inhibitor.(In Vitro):Piroxicam (CP-16171) is a non-steroidal anti-inflammatory drugs, acts as a COX inhibitor, with IC50s of 47, 25 μM for human monocyte COX-1 and COX-2, respectively. Piroxicam (CP-16171) (167, 333, 500 μM) decreases cell population of T24 and the 5637 cells. Piroxicam (CP-16171) (500 μM) also reduces the cell viability of T24 and 5637 cell, and is significantly effective when combined with 0.05 μM carboplatin. The combination also inhibits Ki-67 expression in booth cells.(In Vivo):Piroxicam (CP-16171) (0.3 mg/kg qd 24-h p.o.) reduces tumor volume in 12 of 18 dogs, and such and effect is via induction of apoptosis and reduction in urine basic fibroblast growth factor concentration.

Piroxicam (CP-16171) is a non-steroidal anti-inflammatory drugs, acts as a COX inhibitor, with IC50s of 47, 25 μM for humanmonocyte COX-1 and COX-2, respectively. Piroxicam (CP-16171) (167, 333, 500 μM) decreases cell population of T24 and the 5637 cells. Piroxicam (CP-16171) (500 μM) also reduces the cell viability of T24 and 5637 cell, and is significantly effective when combined with 0.05 μM carboplatin. The combination also inhibits Ki-67 expression in booth cells.

Piroxicam (CP-16171) (0.3 mg/kg qd 24-h p.o.) reduces tumor volume in 12 of 18 dogs, and such and effect is via induction of apoptosis and reduction in urine basic fibroblast growth factor concentration.

Feldene | Larapam | NSC 666076

Chromatin/Epigenetic

COX

COX

Inflammation/Immunology

——

36322-90-4

331.35

C15H13N3O4S

>98% (HPLC)

Ethanol: 1 mg/mL (3.01 mM); DMSO: 66 mg/mL (199.18 mM)

CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3

4-hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide

(-20℃)

With Ice Pack

≥ 2 years